Table 1.
Therapeutic Strategies Targeting Lipotoxicity in NAFLD
| Target | Mechanism | Example Drug |
|---|---|---|
| FXR | Agonist: improve insulin sensitivity; anti‐inflammatory and antifibrotic | Obeticholic acid |
| Acetyl‐CoA carboxylase 1/2 | Antagonist: decrease DNL | PF‐05221304 |
| FGF19/21 | Agonist: decrease bile acid synthesis; anti‐inflammatory and antifibrotic | NGM282 |
| PPARα/γ/δ | Agonist: increase fatty acid oxidation; improve IR; anti‐inflammatory | Elafibrinor |
| Steroyl CoA‐desaturase 1 | Antagonist: decrease DNL | Aramchol |
| Thyroid hormone receptor β | Agonist: decrease circulating lipids | MGL‐3196 |
| Niacin‐R | Agonist: decrease lipolysis in adipose tissue; decrease TG synthesis and increase fatty acid oxidation | Niacin |
| Sirutin‐1 | Agonist: decrease DNL; increase fatty acid oxidation; anti‐inflammatory | Resveratrol |
| Ketohexokinase | Antagonist: decrease DNL | PF‐06835919 |